← back to search

Jiliang Qiu

Sun Yat-sen University · CN
Area of research
Hepatology · Surgery
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Liver Disease Diagnosis and Treatment, and Ferroptosis and cancer prognosis.
h-index
24
citations
2,122
works
81
NIH funding
primary concept
email

Recent publications

Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules
Hepatology 2025cited by 2position: middledoi
Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling
Nature Communications 2024cited by 40position: middledoi
Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study
International Journal of Surgery 2024cited by 33position: middledoi
m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma
Journal of Experimental & Clinical Cancer Research 2024cited by 22position: middledoi
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
International Immunopharmacology 2024cited by 19position: lastdoi
TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
International Journal of Surgery 2023cited by 131position: middledoi
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
Nature Communications 2023cited by 81position: middledoi
METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition
Cell Death Discovery 2023cited by 26position: lastdoi
S100A9 Derived from Chemoembolization‐Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression
Advanced Science 2022cited by 72position: middledoi
Additional file 1 of Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
Figshare 2022cited by 0position: middledoi
Deep Learning With <scp>3D</scp> Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma
Journal of Magnetic Resonance Imaging 2021cited by 78position: middledoi
Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
Annals of Surgery Open 2021cited by 73position: middledoi
Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
Journal of Experimental & Clinical Cancer Research 2021cited by 58position: middledoi
Additional file 1 of Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
Figshare 2021cited by 0position: middledoi
Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma
Theranostics 2020cited by 90position: middledoi
Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis
Alimentary Pharmacology & Therapeutics 2018cited by 122position: middledoi
Nomogram to Predict Survival of Patients With Recurrence of Hepatocellular Carcinoma After Surgery
Clinical Gastroenterology and Hepatology 2017cited by 74position: middledoi
SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice
Gastroenterology 2012cited by 111position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yunfei Yuan · Sun Yat-sen University16 papers (2012–2024)Wei He · Boston Children's Hospital12 papers (2017–2024)Dinglan Zuo · Sun Yat-sen University10 papers (2018–2024)Yunxing Shi · Sun Yat-sen University10 papers (2020–2024)Chenwei Wang · Baylor College of Medicine9 papers (2018–2024)Binkui Li · Sun Yat-sen University8 papers (2017–2024)Yuanping Zhang · Institute of Coal Chemistry7 papers (2018–2022)Zhiwen Yang · Tongji University7 papers (2018–2023)Yadi Liao · Northeast Forestry University6 papers (2020–2023)Yuxiong Qiu · Sun Yat-sen University6 papers (2020–2024)Wenwu Liu · Shenyang Pharmaceutical University6 papers (2018–2022)Binkui Li · Sun Yat-sen University5 papers (2021–2024)Yun Zheng · Zhejiang Chinese Medical University5 papers (2017–2024)Yichuan Yuan · Central University of Finance and Economics4 papers (2021–2024)Yi Niu · Ministry of Education of the People's Republic of China4 papers (2022–2024)Ruhai Zou · Sun Yat-sen University4 papers (2017–2024)Zhiyu Qiu · Sun Yat-sen University4 papers (2021–2024)Kai Li · South China Agricultural University3 papers (2021–2023)Yongjin Wang · Nanjing University of Posts and Telecommunications3 papers (2018–2021)Yichuan Yuan · Sun Yat-sen University3 papers (2020–2023)